PharVision Advisers’s Janus Henderson JHG Stock Holding History

PharVision Advisers’s Portfolio JHG Stock Details JHG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,384	Closed	-$240K	–	851
2025 Q3	$240K	Buy	+5,384	New	+$233K	0.13%	361
2025 Q2	–	Sell	-10,123	Closed	-$366K	–	356
2025 Q1	$366K	Buy	+10,123	New	+$417K	0.51%	62

Other funds holding JHG

TFM

Trian Fund Management New York $4.23B AUM 31.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PharVision Advisers's JHG Position: Q4 2025 in Review

PharVision Advisers sold out of Janus Henderson (JHG) in Q4 2025, closing a stake of 5,384 shares — an estimated $240K sold.

PharVision Advisers first reported a position in JHG in Q1 2025 and held it in 2 quarters. The position peaked at $366K in Q1 2025. 468 funds tracked by Wall St. Rank hold JHG as of Q4 2025.

PharVision Advisers reported no remaining Janus Henderson position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 5,384 Janus Henderson shares in Q4 2025, an estimated $240K.
PharVision Advisers first reported a position in Janus Henderson in Q1 2025 and held it in 2 quarters.
PharVision Advisers's Janus Henderson position peaked at $366K in Q1 2025.
468 funds tracked by Wall St. Rank held Janus Henderson as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.